Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.
Yoshihiko YanoAtsushi YamamotoTakuya MimuraSaeko KushidaSeiya HirohataSeitetsu YoonHirotaka HiranoSoo Ki KimYuri HatazawaKenji MomoseHiroki HayashiTakuo KadoKatsuhisa NishiHidenori TanakaTakanori MatsuuraRyutaro YoshidaNaoki AsajiEiichiro YasutomiYuuki ShiomiAkihiro MinamiShohei KomatsuTakumi FukumotoYoshihide UedaYuzo KodamaPublished in: JGH open : an open access journal of gastroenterology and hepatology (2023)
Not only factors before therapy but also treatment response and the appearance of AEs are involved in OS for atezolizumab/bevacizumab combination therapy. Although the development of AEs also contributed to OS, appropriate management of AEs is important to avoid discontinuing treatment with this combination.